'For quarter ending June 2024, consolidated Net sales (including other operating income) of Ipca Laboratories has increased 32.01% to Rs 2092.63 crore compared to quarter ended June 2023. Sales of India segment has gone up 13.01% to Rs 1,006.47 crore (accounting for 48.10% of total sales). Sales of Outside India segment has gone up 56.37% to Rs 1,086.16 crore (accounting for 51.90% of total sales). Operating profit margin has declined from 19.41% to 18.77%, leading to 27.66% rise in operating profit to Rs 392.72 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 26.64% to 25.81%. Purchase of finished goods cost fell from 7.46% to 5.62%. Employee cost increased from 22.02% to 23.09%. Other expenses rose from 24.93% to 26.91%.
Other income fell 54.05% to Rs 20.61 crore. PBIDT rose 17.27% to Rs 413.33 crore. Provision for interest...
Pleaselogin & subscribe to view the full report.
More Reports
|
|